OBJECTIVES: The accuracy and precision of glomerular filtration rate (GFR) estimating equations based on plasma creatinine (GFR(cr)), cystatin C (GFR(cys)) and the combination of these markers (GFR(cr-cys)) have recently been assessed in HIV-infected individuals. We assessed the associations of GFR, estimated by these three equations, with clinical events in HIV-infected individuals. METHODS: We compared the associations of baseline GFR(cr), GFR(cys) and GFR(cr-cys) [using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations] with mortality, cardiovascular events (CVEs) and opportunistic diseases (ODs) in the Strategies for the Management of Antiretroviral Therapy (SMART) study. We used Cox proportional hazards models to estimate unadjusted and adjusted hazard ratios per standard deviation (SD) change in GFR. RESULTS: A total of 4614 subjects from the SMART trial with available baseline creatinine and cystatin C data were included in this analysis. Of these, 99 died, 111 had a CVE and 121 had an OD. GFR(cys) was weakly to moderately correlated with HIV RNA, CD4 cell count, high-sensitivity C-reactive protein, interleukin-6, and D-dimer, while GFR(cr) had little or no correlation with these factors. GFR(cys) had the strongest associations with the three clinical outcomes, followed closely by GFR(cr-cys), with GFR(cr) having the weakest associations with clinical outcomes. In a model adjusting for demographics, cardiovascular risk factors, HIV-related factors and inflammation markers, a 1-SD lower GFR(cys) was associated with a 55% [95% confidence interval (CI) 27-90%] increased risk of mortality, a 21% (95% CI 0-47%) increased risk of CVE, and a 22% (95% CI 0-48%) increased risk of OD. CONCLUSIONS: Of the three CKD-EPI GFR equations, GFR(cys) had the strongest associations with mortality, CVE and OD.
OBJECTIVES: The accuracy and precision of glomerular filtration rate (GFR) estimating equations based on plasma creatinine (GFR(cr)), cystatin C (GFR(cys)) and the combination of these markers (GFR(cr-cys)) have recently been assessed in HIV-infected individuals. We assessed the associations of GFR, estimated by these three equations, with clinical events in HIV-infected individuals. METHODS: We compared the associations of baseline GFR(cr), GFR(cys) and GFR(cr-cys) [using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations] with mortality, cardiovascular events (CVEs) and opportunistic diseases (ODs) in the Strategies for the Management of Antiretroviral Therapy (SMART) study. We used Cox proportional hazards models to estimate unadjusted and adjusted hazard ratios per standard deviation (SD) change in GFR. RESULTS: A total of 4614 subjects from the SMART trial with available baseline creatinine and cystatin C data were included in this analysis. Of these, 99 died, 111 had a CVE and 121 had an OD. GFR(cys) was weakly to moderately correlated with HIV RNA, CD4 cell count, high-sensitivity C-reactive protein, interleukin-6, and D-dimer, while GFR(cr) had little or no correlation with these factors. GFR(cys) had the strongest associations with the three clinical outcomes, followed closely by GFR(cr-cys), with GFR(cr) having the weakest associations with clinical outcomes. In a model adjusting for demographics, cardiovascular risk factors, HIV-related factors and inflammation markers, a 1-SD lower GFR(cys) was associated with a 55% [95% confidence interval (CI) 27-90%] increased risk of mortality, a 21% (95% CI 0-47%) increased risk of CVE, and a 22% (95% CI 0-48%) increased risk of OD. CONCLUSIONS: Of the three CKD-EPI GFR equations, GFR(cys) had the strongest associations with mortality, CVE and OD.
Authors: Gary L Myers; W Greg Miller; Josef Coresh; James Fleming; Neil Greenberg; Tom Greene; Thomas Hostetter; Andrew S Levey; Mauro Panteghini; Michael Welch; John H Eckfeldt Journal: Clin Chem Date: 2005-12-06 Impact factor: 8.327
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: W M El-Sadr; B Grund; J Neuhaus; A Babiker; C J Cohen; J Darbyshire; S Emery; J D Lundgren; A Phillips; J D Neaton Journal: Ann Intern Med Date: 2008-09-02 Impact factor: 25.391
Authors: Christina M Wyatt; Jonathan A Winston; Carlos D Malvestutto; Dawn A Fishbein; Irina Barash; Alan J Cohen; Mary E Klotman; Paul E Klotman Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Daniel A Duprez; Jacqueline Neuhaus; Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel Nixon; Nicholas I Paton; Ronald J Prineas; James D Neaton Journal: PLoS One Date: 2012-09-10 Impact factor: 3.240
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Chris T Longenecker; Douglas Kitch; Paul E Sax; Eric S Daar; Camlin Tierney; Samir K Gupta; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Jeffrey J Weiss; Ioannis Konstantinidis; Anna Boueilh; Daniel S Fierer; Donald Gardenier; Mark G Barber; Tony Kang; Anna Kress; Katherine Ericson; Marlene C Lira; Marina P Yostos; Hillary R Bogner; Juan P Wisnivesky; Christina M Wyatt Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Eric A Secemsky; Rebecca Scherzer; Elaine Nitta; Alan H B Wu; David C Lange; Steven G Deeks; Jeffrey N Martin; James Snider; Peter Ganz; Priscilla Y Hsue Journal: JACC Heart Fail Date: 2015-07-08 Impact factor: 12.035
Authors: Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt Journal: Kidney Int Date: 2018-02-03 Impact factor: 10.612
Authors: M Hentzien; M Dramé; C Allavena; C Jacomet; M-A Valantin; A Cabié; L Cuzin; D Rey; P Pugliese; F Bani-Sadr Journal: J Nutr Health Aging Date: 2016-04 Impact factor: 4.075
Authors: Chris T Longenecker; Corrilynn O Hileman; Nicholas T Funderburg; Grace A McComsey Journal: Clin Infect Dis Date: 2014-07-11 Impact factor: 9.079
Authors: Mitchell McClean; Petra Buzkova; Matthew Budoff; Michelle Estrella; Matthew Freiberg; Howard N Hodis; Frank Palella; Cecilia Shikuma; Wendy S Post; Samir Gupta Journal: J Acquir Immune Defic Syndr Date: 2020-12-01 Impact factor: 3.771